scdom wrote:Hi, I thought would share our experience with long term psoriasis and colloidal silver.
My partner had psoriasis on her arms and legs from age 16 thru to age 39.
She used soaps, acids and abrasives to keep the areas somewhat under control.
I introduced her to colloidal silver ($20 or so from chemists and health food shops). She applied it regularly on the affected areas and also started drinking it. (it tastes like water and you can't OD.)
The end result was that after 4-5 months the psoriasis was virtually nonexistent and, 4 years later, has not returned.
We take colloidal silver regularly as an overall wellness thing but she no longer needs to apply it to her skin although it is always used for cuts and abrasions.
Google it and see for yourself. We have put lots of peolple onto it with amazing results and I have personally been using it for years.
Dear Scdom,
Thanks for your input and joining our forum. But there has been heavy criticism of products containing Colloidal Silver. Infact, the FDA in the USA has banned the product I believe. you can most definitely over dose pn such products.
Taking even small quantities of colloidal silver into the body can cause the skin to be permanently discolored in a medical condition called argyria. The skin and internal organs retain the silver and turn a dull gray.
Argyria Definition;
A permanent ashen-gray discoloration of the skin, conjunctiva, and internal organs resulting from long-continued use of silver salts. (Dorland, 27th ed)
Original article can be found here;
http://www.fda.gov/bbs/topics/ANSWERS/ANS00971.html but I have included below for convenience.
FDA: Food and Drug Administration
U.S. Department of Health and Human Services
Public Health Service 5600 Fishers Lane Rockville, MD 20857
--------------------------------------------------------------------------------
FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.
--------------------------------------------------------------------------------
FDA ISSUES FINAL RULE ON OTC DRUG PRODUCTS CONTAINING COLLOIDAL SILVER
The FDA has issued a Final Rule declaring that all over- the-counter (OTC) drug products containing colloidal silver or silver salts are not recognized as safe and effective and are misbranded.
Colloidal silver is a suspension of silver particles in a colloidal (gelatinous) base. In recent years, colloidal silver preparations of unknown formulation have been appearing in stores. These products are labeled to treat adults and children for diseases including HIV, AIDS, cancer, tuberculosis, malaria, lupus, syphilis, scarlet fever, shingles, herpes, pneumonia, typhoid, tetanus and many others.
According to the Final Rule, a colloidal silver product for any drug use will first have to be approved by FDA under the new drug application procedures. The Final rule classifies colloidal silver products as misbranded because adequate directions cannot be written so that the general public can use these drugs safely for their intended purposes. They are also misbranded when their labeling falsely suggests that there is substantial scientific evidence to establish that the drugs are safe and effective for their intended uses.
The indiscriminate use of colloidal silver solutions has resulted in cases of argyria, a permanent blue-gray discoloration of the skin and deep tissues.
Colloidal silver ingredients and silver salts include silver proteins, mild silver protein, strong silver protein, silver chloride, and silver iodide. The dosage form of these colloidal silver products is usually oral, but product labeling also contains directions for topical and, occasionally, intravenous use.
In reaching its decision, FDA considered all of the information described in the proposed rule (October 15, 1996) and submitted by the public in response to that proposal, the Final Rule becomes effective on September 16, 1999, 30 days after publication.